Kabra Drugs Ltd (KABRADG) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Kabra Drugs Ltd on NSE and BSE, with an AI summary of each filing.
Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....
Intimation · 06 Nov 2026, 5:30 am
Aanjaay Industries Schedules Board Meeting on 6th Nov'26 to Consider Q2 Results Aanjaay Industries Limited (formerly Kabra Drugs Limited) has informed BSE that a meeting of its Board of Directors is scheduled for 6th Nov'26. The board will convene primarily to consider and approve the company's unaudited financial results for the quarter ended 30th Sep'26, alongside other routine business matters.
Scrutinizers Report
Annual General Meeting · 01 Oct 2026, 9:42 pm
Aanjaay Industries Shareholders Approve All AGM Resolutions with Requisite Majority Aanjaay Industries Limited announced the voting results for its 37th AGM held on 30th Sep'26. Shareholders approved all four resolutions with overwhelming support: adoption of audited financial statements for FY26 (99.87% in favor), re-appointment of retiring director Mr. Kuniamuthur Nanjappan Anand (99.84% in favor), appointment of Ms. Moonam Kapoor as Non-Executive Independent Director (99.56% in favor), and appointment of Mrs. Twinkle Agarwal as Secretarial Auditor (99.82% in favor). One invalid vote of 6,58,500 shares cast by an interested director was excluded for Resolution 2.
Proceedings of Annual General Meeting
Annual General Meeting · 30 Sept 2026, 3:07 pm
Reg. 34 (1) of Annual Report for the financial year 2025-2026
Others (Uncategorized) · 09 Sept 2026, 12:46 am
Notice 37th Annual General Meeting of the Company
Annual General Meeting · 08 Sept 2026, 12:13 am
Appointment of Internal Auditor of the Company
Change in Auditor · 03 Sept 2026, 12:18 am
Aanjaay Industries Appoints Karthik L & Associates as Internal Auditor for FY27 Aanjaay Industries Limited appointed M/s Karthik L & Associates as Internal Auditor for FY26-27, effective 2nd Sep'26. Led by Karthik Loganathan, the firm provides over six years of statutory audit, taxation, and financial management expertise across diverse sectors including aviation, engineering, and real estate. This SEBI-mandated compliance move strengthens internal oversight, financial reporting, and corporate governance for the upcoming fiscal year. Crucially for stakeholders, the newly appointed auditor maintains strict independence, disclosing zero existing relationships with any of the company's current board directors.
Appointment of Secretarial Auditor of the Company
Change in Auditor · 03 Sept 2026, 12:17 am
Aanjaay Industries Appoints Twinkle Agarwal as Secretarial Auditor Aanjaay Industries Ltd appointed Mrs. Twinkle Agarwal as Secretarial Auditor, effective 2nd Sep'26, to conduct audits for the financial years 2026-27 through 2027-31. This board-approved appointment ensures ongoing compliance with the Companies Act and SEBI regulations. Mrs. Agarwal, a practicing Company Secretary, brings extensive expertise in corporate governance, securities laws, and forensic audits across listed and unlisted entities. The company confirmed she has no relationships with existing directors, ensuring regulatory independence.
Outcome of Board Meeting held on 02nd September 2026
Outcome · 03 Sept 2026, 12:08 am
Aanjaay Industries Approves 37th AGM, Book Closure, and Key Director Appointments On 2nd Sep'26, Aanjaay Industries scheduled its 37th AGM for 30th Sep'26, setting book closure from 24th Sep'26 to 30th Sep'26 and the voting cut-off date as 23rd Sep'26. The board approved FY26 governance reports and announced key leadership updates, including the re-appointment of K.N. Anand and appointment of Moonam Kapoor as Directors. Additionally, Karthik L & Associates was appointed as internal auditor for FY27, while Twinkle Agarwal was named secretarial auditor for a five-year term from FY27 to FY31.
Intimation regarding change in resgistered Office of the Company
Others (Uncategorized) · 29 Aug 2026, 10:33 pm
Aanjaay Industries Relocates Registered Office to Chennai Aanjaay Industries Limited (BSE: 524322) has shifted its registered office from Indore, Madhya Pradesh, to Chennai, Tamil Nadu, effective 28th Aug'26. The move follows approval from the Board of Directors and the Regional Director, with necessary statutory compliances completed. The new address is No. 3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai - 600033. This change in jurisdiction transfers the company from ROC Gwalior to ROC Chennai. All future communications should be directed to the new Chennai address.
Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 ,inter alia, to consider and approve Intimation of Board Meeting to ....
Intimation · 27 Aug 2026, 7:43 pm
Aanjaay Industries Board Meeting on 02 Sep'26 for FY26 Reporting and Appointments Aanjaay Industries has scheduled a board meeting for 02 Sep'26 to approve the Director's and Corporate Governance reports for the financial year ended 31 Mar'26. The agenda includes finalizing details for the upcoming Annual General Meeting (AGM), such as fixing the cut-off date for voting. Key considerations also involve the re-appointment of Director Mr. Kuniamuthur Nanjappan Anand, the appointment of Ms. Moonam Kapoor as a Director, and the appointment of internal and secretarial auditors for FY27.
Reconstitution of the Composition of the Board & Committees of Regulation 30 of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 18 Aug 2026, 11:57 pm
Aanjaay Industries Announces Board and Committee Reconstitution Aanjaay Industries (BSE: 524322) announced the reconstitution of its Board of Directors and key committees, effective 12th Aug'26. The board comprises five members, including three Non-Executive Independent Directors. Key committee chairpersons are now: Nikita Sinha for the Audit Committee, Ritu Tiwari for the Nomination and Remuneration Committee, and Moonam Kapoor for the Stakeholders Relationship Committee. The Audit Committee composition includes an Executive Director, Kuniamuthur Nanjappan Anand, alongside two independent directors, which may be a point of governance scrutiny.
Resignation of director of Ms. Anand Anitha
Change in Management · 13 Aug 2026, 1:20 am
Aanjaay Industries (Kabra Drugs) Director Resigns Aanjaay Industries Limited (formerly Kabra Drugs Limited) announced the resignation of Ms. Anand Anitha (DIN: 0240505) from her position as Director, effective 12 Aug'26. The company's board approved the resignation, which was attributed to personal reasons. Ms. Anitha confirmed there were no other material reasons for her departure. According to the disclosure, she does not hold any directorships or committee memberships in other listed entities, suggesting minimal broader market impact from this specific board change.
Undertaking for Non-Applicability of Reg 32
Others (Uncategorized) · 13 Aug 2026, 12:58 am
Aanjaay Industries Certifies Non-Applicability of SEBI Reg 32 for Q1 FY27 Aanjaay Industries Limited (BSE: 524322) has certified to the BSE on 12th Aug'26 that SEBI's Regulation 32 is not applicable for the quarter ended 30th Jun'26. This is because the company did not issue any shares through a public issue, rights issue, or preferential issue during the period. Therefore, there are no proceeds from such issues to report on, and no statement of deviation or variation in the use of funds is required for Q1 FY27. This is a routine compliance update.
Financials results
Financial Result · 13 Aug 2026, 12:35 am
Aanjaay Industries Reports Strong Q1 FY27 Results Aanjaay Industries posted a net profit of ₹2.12 crore for Q1 FY27 ended 30th Jun'26, a significant turnaround from a ₹0.50 crore loss YoY. Revenue from operations surged 546% YoY to ₹46.22 crore. On a QoQ basis, revenue grew 30.5% from ₹35.41 crore, while net profit doubled from ₹1.06 crore. The company reported a basic EPS of ₹0.90 for the quarter, compared to a loss per share of ₹(0.21) in the prior-year period. Total expenses stood at ₹43.45 crore.
Outcome of Board Meeting held on 12th August 2026
Outcome · 13 Aug 2026, 12:28 am
Kabra Drugs Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakhs) ■ Revenue: 4,622 (+546.4% YoY | +30.5% QoQ) ■ EBITDA: 279 (Loss to Profit YoY | +108.3% QoQ) ■ EBITDA Margin (%): 6.0 (Loss to Profit YoY | +225 bps QoQ) ■ PAT: 212 (Loss to Profit YoY | +99.7% QoQ) ■ EPS (INR): 0.90 (Loss to Profit YoY | +100.0% QoQ)
Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Board Meeting to be held on 12-August-2026
Intimation · 12 Aug 2026, 5:30 am
Aanjaay Industries Board Meeting to Approve Q1FY27 Results and Director Resignation Aanjaay Industries has scheduled a Board of Directors meeting on 12th Aug'26 to consider and approve the unaudited financial results for the quarter ended 30th Jun'26. The agenda also includes the resignation of Director Ms. Anand Anitha. The trading window for insiders has been closed until 48 hours after the results are announced.
Fresh Certificate of Incorporation pursuant to Change of Name.
Others (Uncategorized) · 07 Jul 2026, 5:49 pm
Kabra Drugs Limited Renamed to Aanjaay Industries Limited Kabra Drugs Limited (BSE: 524322) has officially changed its name to Aanjaay Industries Limited, effective from 06 Jul'26. The change follows shareholder approval received on 12 Jun'26 and the subsequent issuance of a fresh Certificate of Incorporation by the Ministry of Corporate Affairs. This corporate action reflects a potential shift in the company's strategic focus or branding, a key development for investors monitoring its future direction. The company's CIN remains L02423MP1989PLC005438. Updated corporate documents will be available on the company website.
Press Release on Letter of Intent from Goverment of Chhattisgarh for Rs.200 Crore Pharmaceutical Manufacturing Project
Press Release · 14 Jun 2026, 10:17 pm
Kabra Drugs Receives LOI for ₹200 Crore Pharmaceutical Project in Chhattisgarh Kabra Drugs received a Letter of Intent (LOI) on 12 Jun'26 from the Chhattisgarh government for a proposed ₹200 crore pharmaceutical manufacturing facility. Located at Nava Raipur Pharma Park, the project aligns with the company's expansion strategy to enhance its manufacturing footprint and production capacity. The investment is expected to generate approximately 250 direct and indirect jobs. Final execution is subject to definitive agreements and necessary approvals, with the company anticipating benefits from state government incentives and policies.
Revised due to typo error in date
Others (Uncategorized) · 13 Jun 2026, 11:14 pm
Kabra Drugs Receives LOI for ₹200 Crore Pharma Plant in Chhattisgarh Kabra Drugs received a Letter of Intent on 12 Jun'26 from the Chhattisgarh Government for a proposed ₹200 crore investment in a pharmaceutical manufacturing facility. Located at Nava Raipur Pharma Park, the project aims to expand manufacturing capacity, strengthen operational capabilities, and support long-term growth. The investment is expected to generate approximately 250 jobs and is contingent upon definitive agreements and regulatory approvals. The company anticipates the project will boost its manufacturing footprint and enhance revenue significantly.
Pharmaceutical Manufacturing Project at Nava Raipur Pharma Park.
Others (Uncategorized) · 13 Jun 2026, 9:26 pm
Kabra Drugs to Invest ₹200 Cr in New Chhattisgarh Pharma Facility Kabra Drugs received a Letter of Intent from the Chhattisgarh government on 12 Jun'26 for a proposed ₹200 Crore investment. The project involves establishing a new pharmaceutical manufacturing facility at Nava Raipur Pharma Park. It is expected to expand manufacturing capacity, boost revenue, and generate approximately 250 jobs. The project's progression is contingent on definitive agreements and regulatory approvals. The company anticipates government incentives covering roughly 60% of the project, subject to applicable state policies.
Press Release on Audited Financial Results for Quarter and Year ended 31 March 2026
Press Release · 31 May 2026, 2:26 am
Kabra Drugs Reports Exceptional FY26 Turnaround with Strong YoY Growth Kabra Drugs announced a significant turnaround for the year ended 31st Mar'26, posting a total income of ₹93.23 crore, up 14,463.06% YoY. The company turned profitable with EBITDA at ₹5.82 crore and PAT at ₹4.96 crore, compared to losses in FY25. For Q4 FY26, total income surged 5,448.13% YoY to ₹35.52 crore, with PAT growing 170.15% to ₹1.06 crore. The company plans strategic expansion into pharmaceutical manufacturing and AI-led defence technologies to sustain growth momentum.
Non-Applicability of Regulations 32 of SEBI (LODR)
Others (Uncategorized) · 30 May 2026, 1:11 am
Kabra Drugs Confirms No Share Issuance in Q4 FY26 Kabra Drugs Limited (BSE: 524322) filed an undertaking on 29th May'26, confirming the non-applicability of SEBI's Regulation 32 for the quarter ended 31st Mar'26. The company certified that it had not raised funds via a public issue, rights issue, or preferential issue during the quarter. Consequently, the requirement to submit a statement detailing the use of proceeds and deviations from stated objectives does not apply. This indicates no equity dilution or major fundraising activity from these sources in Q4 FY26.
Financial results for quarterly & year ended 31st March 2026.
Financial Result · 30 May 2026, 12:54 am
Kabra Drugs Reports FY26 Results, Posts Significant Profit Turnaround Kabra Drugs announced a strong turnaround for the year ended 31st Mar'26, posting a Net Profit of Rs 495.98 lakhs compared to a loss of Rs 108.56 lakhs in FY25. For Q4 FY26, the company reported a Net Profit of Rs 106.33 lakhs, a 170% YoY increase from Rs 39.36 lakhs. Revenue from operations for FY26 stood at Rs 9,274.00 lakhs. The company's EPS for the full year improved significantly to Rs 2.09, rebounding from a negative EPS of Rs (0.99) in the previous year.
Outcome of board meeting
Outcome · 30 May 2026, 12:34 am
Kabra Drugs Reports Q4FY26 and Full-Year FY26 Audited Financial Results For FY26, Kabra Drugs reported a PAT of Rs. 495.98 lakhs, a significant turnaround from a Rs. 108.56 lakhs loss in FY25. Revenue from operations for the year stood at Rs. 9,274.00 lakhs. For the quarter ended 31st Mar'26 (Q4FY26), the company posted a PAT of Rs. 106.33 lakhs on revenue of Rs. 3,540.60 lakhs, compared to a PAT of Rs. 39.36 lakhs YoY. The board approved the audited financial statements on 29th May'26. Basic EPS for FY26 was Rs. 2.09.
Outcome of board meeting
Outcome · 30 May 2026, 12:32 am
Kabra Drugs Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 3,541 (+16.4% QoQ) ■ EBITDA: 134 (Loss to Profit YoY | -45.2% QoQ) ■ EBITDA Margin (%): 3.8 (-425 bps QoQ) ■ PAT: 106 (+170.1% YoY | -51.7% QoQ) ■ EPS (INR): 0.45 (+114.3% YoY | -51.6% QoQ)